In this week’s episode of Healthspan Academy, I had a fascinating chat with Dr Dan Karlin about the latest info on the applications of psychedelics for improving cognitive function and mental health. We talked about the most common outcomes, proper dosing, and designing the ideal environment and experience. Dr. Karlin summarized what we currently know about the mechanism and the relation to our neurotransmitters and neuroplasticity. We also talked about future applications and when we could expect some of these psychedelics to come to market.
Dr. Dan Karlin joined MindMed as Chief Medical Officer in February 2021 following MindMed’s acquisition of HealthMode, the company he co-founded and led as CEO. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.
Dr. Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics working at the intersection of health and technology in the pharmaceutical and biotech industry on psychiatric drug development, novel instruments, data, and analysis-driven strategies for clinical drug development; and in clinical medicine where he practices psychiatry and addiction medicine, teaches clinical skills and quality improvement, develop novel technologies, and creates tech-enabled care models and practices.
Prior to joining HealthMode, he established and led Pfizer’s Digital Medicine and Innovation Research Lab’s clinical, informatics, and regulatory strategy. He also worked at Pfizer as the Global Clinical Lead for psychiatry clinical compounds. He previously served as Column Health’s founder and Chief Medical Officer, a leading technology-enabled psychiatry and addiction practice.
Dr. Dan serves as a strategic advisor to several pharmaceutical, biotech, and health technology firms. He is also a founding Advisor to the Digital Biomarkers Journal, the founder and Board Member of the Digital Medicine Society (DiMe), and a member of the Critical Path Alzheimer’s Disease, MJFF, and Mental Health IT committees at the APA.
Currently, he is also an Assistant Professor of Psychiatry at Tufts University School of Medicine.
*** Please note that the content discussed in this podcast is intended for self-education and is not to be interpreted as medical advice.